Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer - PubMed (original) (raw)
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer
Daniel Zips et al. Radiother Oncol. 2012 Oct.
Free article
Abstract
Purpose: To explore in a prospective trial the prognostic value of hypoxia imaging before and during radiochemotherapy in patients with locally advanced head and neck cancer.
Patients and methods: Twenty-five patients with stage III/IV head and neck cancer were investigated with [(18)F]-fluoromisonidazole (FMISO) PET/CT at four time points during radiochemotherapy (baseline, 8-10 Gy, 18-20 Gy,50-60 Gy). FMISO PET/CT image parameters were extracted including maximum-tumour-to-background (TBR(max)) and thresholded volume at different TBR ratios. CT volume and baseline FDG-PET/CT image parameters were also included. Parameters at all time points were investigated for their prognostic value with the local-progression-free-survival endpoint (LPFS). Significance was evaluated with multivariate Cox (including clinical parameters) and Log-rank tests.
Results: FMISO-image parameters were found to have a strong association with the LPFS endpoint, and were strongest at the week 1 and 2 time points (p = 0.023-0.048 and 0.042-0.061 respectively on multivariate Cox). Parameters measured at baseline were only significant on univariate analysis. None of the clinical parameters, and also FDG- or CT-delineated volumes, were significantly associated with LPFS.
Conclusion: This prospective, exploratory study demonstrated that FMISO-PET/CT imaging during the initial phase of treatment carries strong prognostic value. FMISO-PET/CT imaging at 1 or 2 weeks during treatment could be promising way to select patients that would benefit from hypoxia modification or dose-escalated treatment. A validation study is on-going.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S, Perrin R, Seidlitz A, Bandurska-Luque A, Zschaeck S, Zöphel K, Krause M, Steinbach J, Kotzerke J, Zips D, Troost EGC, Baumann M. Löck S, et al. Radiother Oncol. 2017 Sep;124(3):533-540. doi: 10.1016/j.radonc.2017.08.010. Epub 2017 Aug 23. Radiother Oncol. 2017. PMID: 28843726 - FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Abolmaali N, Seidlitz A, Appold S, Krause M, Steinbach J, Kotzerke J, Zips D, Baumann M, Troost EGC. Bandurska-Luque A, et al. Radiother Oncol. 2019 Jan;130:97-103. doi: 10.1016/j.radonc.2018.09.008. Epub 2018 Oct 4. Radiother Oncol. 2019. PMID: 30293643 - Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC. Löck S, et al. Radiother Oncol. 2019 Jun;135:43-50. doi: 10.1016/j.radonc.2019.02.020. Epub 2019 Mar 9. Radiother Oncol. 2019. PMID: 31015169 - Tumor hypoxia: a new PET imaging biomarker in clinical oncology.
Tamaki N, Hirata K. Tamaki N, et al. Int J Clin Oncol. 2016 Aug;21(4):619-625. doi: 10.1007/s10147-015-0920-6. Epub 2015 Nov 14. Int J Clin Oncol. 2016. PMID: 26577447 Review. - Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review.
Halmos GB, Bruine de Bruin L, Langendijk JA, van der Laan BF, Pruim J, Steenbakkers RJ. Halmos GB, et al. Clin Nucl Med. 2014 Jan;39(1):44-8. doi: 10.1097/RLU.0000000000000286. Clin Nucl Med. 2014. PMID: 24152663 Review.
Cited by
- Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCC.
Rabasco Meneghetti A, Zwanenburg A, Linge A, Lohaus F, Grosser M, Baretton GB, Kalinauskaite G, Tinhofer I, Guberina M, Stuschke M, Balermpas P, von der Grün J, Ganswindt U, Belka C, Peeken JC, Combs SE, Böke S, Zips D, Troost EGC, Krause M, Baumann M, Löck S. Rabasco Meneghetti A, et al. Sci Rep. 2022 Oct 6;12(1):16755. doi: 10.1038/s41598-022-21159-7. Sci Rep. 2022. PMID: 36202941 Free PMC article. - De-Escalation Strategies of (Chemo)Radiation for Head-and-Neck Squamous Cell Cancers-HPV and Beyond.
Rühle A, Grosu AL, Nicolay NH. Rühle A, et al. Cancers (Basel). 2021 May 4;13(9):2204. doi: 10.3390/cancers13092204. Cancers (Basel). 2021. PMID: 34064321 Free PMC article. Review. - [Aggressive radiotherapy de-escalation for HPV-associated oropharyngeal carcinoma based on hypoxia dynamics].
Rühle A, Nicolay NH. Rühle A, et al. Strahlenther Onkol. 2021 Jun;197(6):570-573. doi: 10.1007/s00066-021-01765-6. Epub 2021 Mar 25. Strahlenther Onkol. 2021. PMID: 33765185 Free PMC article. German. No abstract available. - The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation.
Rühle A, Grosu AL, Wiedenmann N, Ruf J, Bieber B, Stoian R, Thomsen AR, Gkika E, Vaupel P, Baltas D, Weber WA, Mix M, Nicolay NH. Rühle A, et al. Clin Transl Radiat Oncol. 2022 Feb 21;33:120-127. doi: 10.1016/j.ctro.2022.02.008. eCollection 2022 Mar. Clin Transl Radiat Oncol. 2022. PMID: 35243023 Free PMC article. - Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.
Stieb S, Eleftheriou A, Warnock G, Guckenberger M, Riesterer O. Stieb S, et al. Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2201-2217. doi: 10.1007/s00259-018-4116-y. Epub 2018 Aug 20. Eur J Nucl Med Mol Imaging. 2018. PMID: 30128659 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical